Daniel R. Chevallard - May 28, 2021 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
CFO and COO
Signature
/s/ Michael Mueller, as Attorney-in-Fact
Stock symbol
VIRX
Transactions as of
May 28, 2021
Transactions value $
$10,800
Form type
4
Date filed
6/1/2021, 05:49 PM
Next filing
Sep 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRX Common Stock Options Exercise $10.8K +12K +26.81% $0.90 56.8K May 28, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Options Exercise $0 -12K -10.83% $0.00 98.8K May 28, 2021 Common Stock 12K $0.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of July 30, 2019 (the "Vesting Commencement Date") and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with Viracta Subsidiary, Inc.'s 2016 Equity Incentive Plan (the "Plan") through each such date.